✦ LIBER ✦

Liver transplantation for patients with hepatitis B: What have we learned from our results?

✍ Scribed by John R. Lake; Teresa L. Wright

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 579 KB
Volume: 13
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840130429

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liver transplantation for hepatitis B: W

Liver transplantation for hepatitis B: What have we learned and what does the future hold?

✍ Fung, John J. ;Rakela, Jorge ;Pinna, Antonio ;Todo, Satoru 📂 Article 📅 1995 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 617 KB

Adefovir dipivoxil for wait-listed and p

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

✍ Eugene Schiff; Ching-Lung Lai; Stephanos Hadziyannis; Peter Neuhaus; Norah Terra 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

Wait-listed (n ϭ 226) or post-liver transplantation (n ϭ 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable

Model for end-stage liver disease (MELD)

Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

✍ Richard B. Freeman Jr.; Robert G. Gish; Ann Harper; Gary L. Davis; John Vierling 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

Determining need for liver transplantation (LT) can be effectively estimated when the actual liver disease is highly likely to cause death in the near future. However, for many conditions, the liver disease itself does not carry a high risk of short-term mortality, and other factors contribute to de